Compare First Trust NASDAQ Cybersecurity ETF (CIBR) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust NASDAQ Cybersecurity ETF vs Summit Therapeutics Inc — how do they compare? First Trust NASDAQ Cybersecurity ETF trades at $100.08, while Summit Therapeutics Inc trades at $15.16 (market cap $12.06B). The key difference: First Trust NASDAQ Cybersecurity ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| CIBR | SMMT | |
|---|---|---|
52-Week High | $100.60 | $26.98 |
52-Week Low | $60.74 | $12.55 |
Market Cap | — | $12.06B |
Sector | — | Health |
Enterprise Value | — | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CIBR trades at $100.39, down 0.21% on the day, with a bullish technical signal driven by moving averages but overbought RSI readings. The ETF benefits from strong cybersecurity spending trends, with global expenditures exceeding $300 billion in 2026 (Gartner, 2026-06-04), and has outperformed the S&P 500 year-to-date. Recent institutional activity shows mixed signals, with Bank of America reducing its stake while First Trust Advisors increased its position.
Outlook remains positive due to secular growth in cybersecurity demand, though high RSI levels suggest near-term consolidation risks. Investment opportunity lies in AI-driven security needs, but concentration in tech and valuation sensitivity are key risks for investors.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About First Trust NASDAQ Cybersecurity ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index includes securities of companies classified as cyber security companies. The fund is non-diversified.
Read more on CIBR →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
